The Europe glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 7.09 Billion in 2024, driven by the rising prevalence rates of type 2 diabetes and obesity along with the supportive regulatory systems in the region. The market is anticipated to grow at a CAGR of 7.30% during the forecast period of 2025-2034, with the values likely to reach USD 14.34 Billion by 2034.
Base Year
Historical Year
Forecast Year
The rising prevalence of diabetes and obesity in European countries is expected to boost the market demand in the forecast period.
The rise in strategic partnerships to accelerate the development of next-generation GLP-1 therapies is projected to support the Europe glucagon-like peptide-1 (GLP-1) agonists market growth.
Increasing government support, ongoing drug innovation, and expanding insurance coverage are poised to influence the market dynamics in the region.
In Europe, many countries are adopting GLP-1 drugs as a key treatment for blood sugar control and weight management. This is augmenting the demand for leading therapies like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and dulaglutide (Trulicity). Further, the market is shifting toward oral and long-acting GLP-1 formulations, as patients prefer fewer injections and more convenient treatment options. Moreover, the increasing government support, ongoing drug innovation, and expanding insurance coverage are projected to fuel the GLP-1 market growth in the region.
Rising Prevalence of Diabetes to Support Market Growth
In the United Kingdom, over 5.8 million people are estimated to be living with diabetes. With nearly 4.6 million diagnosed cases and 1.3 million estimated to be undiagnosed type 2 diabetes patients, the demand for advanced diabetes treatments is increasing. The rising diabetes burden is driving higher adoption of GLP-1 receptor agonists, such as Ozempic, Mounjaro, and Trulicity, across Europe. Moreover, with pharmaceutical companies investing in production and clinical trials, the European market for GLP-1 is set to grow further in the coming years.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Drugs to Witness Substantial Growth
Based on the drugs, the Europe market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. The semaglutide segment holds a significant market share owing to the increasing adoption of the drug for diabetes and obesity treatment coupled with the rising availability of oral and long-acting semaglutide formulations in the region. Dulaglutide, a once-weekly GLP-1 drug for type 2 diabetes, is also widely used across Europe (particularly in Western Europe), due to its cardiovascular benefits and strong physician preference.
Western Europe, including countries like Germany, France, the United Kingdom, Italy, and Spain, covers a substantial market share owing to the well-established healthcare systems and government support for GLP-1 drug coverage. The demand for long-acting and oral GLP-1 treatments is also rising in Central Europe as patients are increasingly preferring more convenient options. In Eastern Europe, consumer awareness and availability of GLP-1 therapies are improving, which is likely to impact market dynamics. Further, the Nordic region, led by Denmark, Sweden, and Norway, has a high demand for GLP-1 drugs, particularly due to Novo Nordisk’s strong presence in Denmark.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly is a key player in the market, especially through its anti-obesity drug Mounjaro. This dual GIP/GLP-1 receptor agonist has demonstrated superior efficacy in glycemic control and weight management compared to traditional GLP-1 therapies. The company is focused on expanding its Europe glucagon-like peptide-1 (GLP-1) agonists market presence through regulatory approvals, clinical trials, and partnerships with healthcare providers.
Sanofi is a French multinational pharmaceutical company headquartered in Paris. It is one of the world's largest drug manufacturers, with a strong presence in diabetes care. The company continues to explore innovative delivery mechanisms and combination therapies for GLP-1 receptor agonists to improve patient adherence and treatment outcomes.
Novo Nordisk, based in Denmark, is a global leader in diabetes care and metabolic disorders. The company is actively investing in R&D, supply chain expansion, and physician education to drive the adoption of its GLP-1 receptor agonist drug candidates (such as Ozempic, Rybelsus, and Wegovy) across Europe.
AstraZeneca is a British-Swedish multinational pharmaceutical company headquartered in Cambridge, United Kingdom. It specializes in oncology, cardiovascular diseases, respiratory conditions, and metabolic disorders. The company is involved in diabetes treatment through GLP-1 receptor agonists and combination therapies.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share